China To Expedite Clinical Trial Approval For Generics
This article was originally published in PharmAsia News
Executive Summary
China’s proposed amendments to the drug registration regulation will simplify and speed up approval for generic clinical trials, in which the onsite inspection by the provincial FDA and sample testing by the drug testing institute will be placed after the review of China FDA.